Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial | Synapse
September 4, 2017Open Access
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Cancer Research UK, Sarcoma UK, and Clinical Trial Unit Kantonsspital St Gallen.